Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-MV in Pediatric Patients With Systemic Viral Infection Following Allo-HSCT
NCT07685457Recruiting
- Sponsor
- LucasBio
- Start
- Feb 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of LB-DTK-MV in BK virus infection, cytomegalovirus infection (CMV) and Epstein-Barr virus infection, sponsored by LucasBio. Primary endpoints: Viral Load at 24 weeks, Immunogenicity Testing at 24 weeks and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
LB-DTK-MV
03
Conditions
BK virus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT07685457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685457.